Applying Precision Genomics to Optimize Cancer Patient Treatment Recommendations
Clinical biomarkers can be valuable tools for assessing prognosis and treatment options for cancer patients. PIK3R1 and POLE are emerging biomarkers in endometrial cancer. In endometrial cancer patients, PIK3R1 mutations are highly prevalent and associated with poor prognosis, but their biochemical effects in the cell are diverse and not well studied. Conversely, detection of a POLE mutation is associated with good prognosis, which guide clinicians to can spare patients from the toxicity of overtreatment. Thus, detecting and understanding these biomarkers are essential for optimizing patient care.
Join us to hear variant scientists from Intermountain Health discuss their use of precision genomics to sequence and analyze patient tumors, and present in-depth findings on PIK3R1 and POLE in the context of endometrial cancer gleaned through the literature using the Mastermind® Genomic Search Engine as part of their workflows.
Virtual event with special guest: Intermountain Health
Prognosis and Potential: How POLE and PIK3R1 Are Changing How We Approach Endometrial Cancer
Thursday, July 13, 2023 | 11am EDT
REGISTER HERE
You Will Learn:
- How biochemical and clinical trial research may shed light on the impacts of PIK3R1 mutations in endometrial cancers
- How POLE mutations are associated with favorable prognosis and improved progression-free survival in endometrial cancer
- How the detection of a POLE mutation can inform treatment recommendations that spare patients with good prognoses from overtreatment
SPEAKERS
|
|
|
|
|
Variant Scientist, Intermountain Health
|
|
|
Aneesa obtained her BS in biology from the University of Portland and her PhD in molecular biosciences from Washington State University. Her dissertation focused on the regulation of DNA double-strand break repair in the laboratory of Dr. Chengtao. Aneesa then went on to serve as a post-doctoral scholar at the University of Utah chemistry department where she investigated the transcriptional regulation of a family of methyl-binding proteins in prostate cancer. She is now a Variant Scientist at Intermountain Precision Genomics where she classifies and curates genomic variants. She is passionate about utilizing complex datasets for clinical applications.
|
|
|
|
|
|
|
|
Variant Scientist, Intermountain Health
|
|
|
Natalie is a Variant Scientist on the Intermountain Precision Genomics team at Intermountain Health. Currently, she specializes in classifying and interpreting genomic variants in both solid and liquid tumors. She holds a PhD in molecular biosciences from Washington State University and a BS from the University of California, Merced.
|
|
|
|
|
|
|
|
Field Application Scientist, Genomenon
|
|
|
Denice is a Field Application Scientist at Genomenon, where she provides technical support and training to Mastermind users at all levels. With a background in germline variant analysis and preimplantation genetics in clinical NGS labs, she turns feedback into function, enabling implementation of Mastermind for a variety of clinical use-cases.
|
|
|
|
Create your free Mastermind account in seconds. With its vast and continuously updated database of genomic evidence in the published literature, Mastermind significantly enhances variant interpretation, streamlines research workflows, and supports more accurate clinical diagnoses. Sign up today to get started with a complimentary trial of Mastermind Professional Edition before the webinar!
|
|
|
About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.
Learn more about Genomenon at genomenon.com and follow them on LinkedIn and Twitter.
